Conjugation of the N/OFQ peptide with the red fluorescent ATTO dye has not altered the functional properties of this peptide. The detectable range of N/OFQATTO in confocal microscopy is such that concentration-dependent binding; binding affinities can be measured.
differentially inhibit synaptic vesicle (SV) exocytosis depending on neurone phenotype, with greater inhibition of excitatory glutamatergic SV release than of inhibitory GABAergic SV release from hippocampal neurones. 3, 4 However, anaesthetic effects on dopamine release from dopaminergic (DA) neurones have not been studied, even though dopaminergic mechanisms have been implicated in emergence from anaesthesia. 5 We investigated the effects of isoflurane on SV release in DA neurones (identified by post hoc tyrosine hydroxylase immunoreactivity) from rat ventral tegmental area (VTA) neurones using live-cell imaging to measure SV exocytosis and Ca 2+ influx. We employed a pH-sensitive variant of eGFP (pHluorin) fused to the luminal domain of the vesicular monoamine transporter (vMAT) to measure exocytosis and the cell permeant fluorescent Ca 2+ indicator Fluo-5F to measure intracellular Ca 2+ concentration.
Isoflurane differentially inhibited SV exocytosis and Ca
2+
influx induced by electrically stimulated action potentials from both DA (by 29 ± 4%, n ¼ 13, p < 0.0001 and 42 ± 3%, n ¼ 6, p < 0.0001, respectively) and non-DA neurones (by 16 ± 5%, n ¼ 10, p < 0.0055 and 58 ± 5%, n ¼ 8, p < 0.0001, respectively). In contrast to other neurotransmitter phenotypes, isoflurane also inhibited SV exocytosis evoked by elevated K + in DA neurones, suggesting a voltage-gated Na + channel (Nav) independent mechanism of anaesthetic action in this neuronal population. This contrasts with SV exocytosis from glutamate or GABA releasing neurones, which requires Nav. SV release is known to be tightly coupled to Ca 2+ entry 6 . contributes to cell death following cerebral ischemia. Activation of NOP by N/OFQ or other small molecule agonists would therefore be predicted to be neuroprotective. Here, we have assessed NOP expression in hippocampal and subcortical regions of the mouse brain by PCR and assessed the effects of activation in an ex vivo model of cerebral ischaemia. We used C57/BL6j neonatal mice, aged 6-9 days. For NOP expression studies, mRNA was extracted from hippocampal Abstracts -e7 and subcortical regions using a tri-reagent methodology, and cDNA formed via reverse transcription. cDNA was probed for NOP relative to the house-keeper gene Beta-actin, using TaqMan probes via QPCR. 3 To investigate the neuroprotective properties of NOP activation, an ex vivo model of cerebral ischemia was used where cortical brain slices were exposed to oxygen and glucose deprivation (OGD) to mimic ischemic damage, in the presence/absence of N/OFQ. Brain slices were immersed in artificial cerebral spinal fluid (aCSF) to recover from slicing prior to OGD exposure in the presence/absence of N/OFQ (1mM) for 40 minutes. Slices were incubated with 2% 2,3,5-triphenyl-2H-tetrazolium chloride (TTC) to visualise infarcted tissue. 4 Area of cell death including hippocampus and sub-cortex but excluding the outer cortex was measured using Imagej software 1.51. NOP receptor mRNA was expressed in both tissues with deltaCt, relative to Beta-actin of 10.52 * 0.25 and 9.62 * 0.65 in hippocampus and sub-cortex respectively (mean þ SEM from 9 mice across 3 litters). Subcortical tissue expressed 1.87 fold more NOP than hippocampal tissue. In an acute model of cerebral ischaemia OGD increased the area of cell death from 25.92 ± 4.09% (in normoxic condition) to 66.02 ± 9.99% (Data are mean ± SEM from 12 neonatal mice, across 4 litters; p<0.01). Treatment with N/OFQ significantly (p<0.01) reduced this ischaemic damage to 39.47 ± 7.82%. The vehicle for N/OFQ, dH 2 O, was ineffective; 72.09 ± 11.87% compared to OGD control.
These data show a neuroprotective role for NOP activation and suggest this pathway as a potential target in acute ischaemic stroke. Further studies, with more metabolically stable NOP agonists are underway and a series of in vivo experiments planned.
